Share this page!

Mac n’ Chise 🧬🦠🧫 Profile picture
Twitter logo
18 May, 5 tweets, 2 min read
I honestly never thought I would see the day I was shamed by other academics for only having a Masters degree. I have hit a roadblock saving to be able to even pursue a PhD while I have been helping my family during COVID. Not having one doesn’t mean I am unqualified to speak.
Those who know me know how much I went through to make it through school with what I had and what my family had. I didn’t grow up with money. I am still paying off my student loans but I’m still trying and will continue to do so. I am proud of how far I have gotten.
Some have asked who and I shouldn’t be worried about shielding these people. I’m tired. I do the best I can with what I have right now. Getting a PhD is a luxury that I cannot meet the needs for yet. Image
I wanted to personally thank everyone who reached out yesterday and continue to do so this morning. I’m still getting to your replies and several DMs. Yesterday was a rough day and I fell a little behind but I am catching up.
Just thank you. The words of encouragement, the support, the kind messages, just everything. It means a lot to me and makes me realized I have some amazing people beside me. You guys are wonderful. I’ll be getting back to posting today.

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Mac n’ Chise 🧬🦠🧫

Mac n’ Chise 🧬🦠🧫 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Mac n’ Chise 🧬🦠🧫 Profile picture
18 May
This is wonderful! Real-world study data out of UCL based on 8,517 people in England and Wales shows 96% of people, who had either Pfizer’s or AstraZeneca’s vaccine developed antibodies 28 to 34 days after their 1st dose. This rose to 99% within 7 to 14 days of their second dose!
Over 9 out of 10 adults in the UK who had either the Pfizer or AstraZeneca vaccine produced antibodies against the virus within a month of their first dose. None of the participants of the study had antibodies prior to their first dose of the vaccine. The study found antibody
rates initially increase quicker among those who have had the Pfizer/BioNTech vaccine than those with the Oxford/AstraZeneca. However, after one month the recipients showed almost identical antibody positivity rates.
Read 6 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
15 May
Extremely welcome news today! A new study from the Indraprastha Apollo Hospital in Delhi, India shows 97.38% of a total of 3,235 HCWs vaccinated with Covishield (AstraZeneca) were protected from COVID-19 infection and the chances of hospitalization after vaccination were 0.06%.
The study was designed to evaluate the frequency of breakthrough infections, and was carried out on healthcare workers who reported to Delhi's Indraprastha Apollo Hospital with symptomatic COVID-19, during the first 100 days of the vaccination drive using the Covishield vaccine.
The results of the study show that break-through infections occur only in a small percentage and these are primarily minor infections that do not lead to severe disease. There were no ICU admissions or deaths reported!
Read 5 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
12 May
A recent study shows that a single dose of AstraZeneca’s vaccine in HCWs previously infected with SARS-CoV-2 serves as an effective immune booster up to at least 11 months post infection and effectively neutralizes WT, and SARS-CoV-2 variants of concern P.1, B.1.1.7, AND B.1.351!
Researchers here compared spike-specific IgG and pseudo-neutralizing spike-ACE2 blocking antibodies against SARS-CoV-2 wild type and variants B.1.1.7, B.1.351, and P.1 following two doses of Pfizer’s vaccine and a single dose of AstraZeneca’s vaccine in 232 healthcare workers
with and without a previous SARS-CoV-2 infection. What they found were that post-vaccine levels of spike-specific IgG AND neutralizing antibodies against the SARS-CoV-2 wild type and all three variants of concern were similar OR indeed higher in participants receiving a single
Read 5 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
11 May
Everyone needs to read this today. Yes, the vaccines ARE working. India is using Covishield (AstraZeneca/SII) and Covaxin. India’s rise in infections appears to be leveling off today via Our World in Data.
The issue is not the vaccines themselves. It’s supply and distribution against a variant that is heavily circulating through a majorly unvaccinated population. Anyone telling you otherwise isn’t bothering to read.
Let’s clear up some confusion on the study on neutralization of variant B.1.617.1 first identified in India (not B.1.617.2 which is the designated variant of concern in the UK) live virus by post-vaccine sera with Moderna/Pfizer. Yes, ALL vaccine sera neutralized the virus.
Read 5 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
10 May
Immunological memory wins! A recent study shows immunity in convalescent individuals will be VERY long lasting and that convalescent individuals who received an mRNA vaccine produced antibodies and memory B-cells that will be protective against circulating SARS-CoV-2 variants!
Here, researchers reported on a cohort of 63 COVID-19-convalescent individuals assessed at 1.3, 6.2 and 12 months after infection, 41% of whom received an mRNA vaccine. In the absence of vaccination, antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2,
neutralizing activity, and the number of RBD-specific memory B-cells remained relatively stable from 6 to 12 months. However, vaccination increased ALL components of the humoral response, and as expected, results in serum neutralizing activities against variants of concern that
Read 9 tweets
Mac n’ Chise 🧬🦠🧫 Profile picture
1 May
Good news all around this morning! Preliminary data shows the vaccines are indeed effective against B.1.617, the variant first identified in India. In addition, the vaccines utilized in Brazil (Coronavac and AstraZeneca) are indeed working and prove to be effective against P.1!
Per the Gupta lab, this gives us good reason to believe vaccination in India will contribute to control of transmission as well as the severe effects of COVID-19. Preprint is not available yet but the thread is encouraging. When the study is up I’ll gladly share it.
Now for Brazil and P.1. As 1st doses were administered to over 95% of 80+ year-olds reaching 49.1% in weeks 5-6 and over 90% after week 9 of the study. (77% CoronaVac, AZ 16%), COVID mortality rate began to decline rapidly DESPITE P.1. being dominate.
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @sailorrooscout has new unrolls!

Check out other threads from @sailorrooscout!

Read all threads by @sailorrooscout

:(